Evidence map›Paper›PMID 29511935›Full record

ArticleInflammation2018

Serum from the Human Fracture Hematoma Contains a Potent Inducer of Neutrophil Chemotaxis.

Okan W Bastian, Mikolaj H Mrozek, Marco Raaben, Luke P H Leenen, Leo Koenderman, Taco J Blokhuis

Open access · hybridAbstract read
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Okan W BastianDepartment of Traumatology, University Medical Center Utrecht, Utrecht, The Netherlands. okanbastian@gmail.com.
Mikolaj H MrozekDepartment of Traumatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Marco RaabenDepartment of Traumatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Luke P H LeenenDepartment of Traumatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Leo KoendermanDepartment of Respiratory Medicine and Laboratory of Translational Immunology (LTI), University Medical Center Utrecht, Utrecht, The Netherlands.
Taco J BlokhuisDepartment of Traumatology, Maastricht University Medical Center, Maastricht, The Netherlands.
University Medical Center Utrecht · NLMaastricht University · NL

Funding

Osteosynthesis and Trauma Care Foundation 2010-TBLLUniversitair Medisch Centrum Utrecht Alexandre Suerman MD/PhD grant
6 · The paper itself

Abstract

A controlled local inflammatory response is essential for adequate fracture healing. However, the current literature suggests that local and systemic hyper-inflammatory conditions after major trauma induce increased influx of neutrophils into the fracture hematoma (FH) and impair bone regeneration. Inhibiting neutrophil chemotaxis towards the FH without compromising the hosts' defense may therefore be a target of future therapies that prevent impairment of fracture healing after major trauma. We investigated whether chemotaxis of neutrophils towards the FH could be studied in vitro. Moreover, we determined whether chemotaxis of neutrophils towards the FH was mediated by the CXCR1, CXCR2, FPR, and C5aR receptors. Human FHs were isolated during an open reduction internal fixation (ORIF) procedure within 3 days after trauma and spun down to obtain the fracture hematoma serum. Neutrophil migration towards the FH was studied using Ibidi™ Chemotaxis

Indexed as

Bacterial ProteinsBone RegenerationChemotaxisFracture HealingFractures, BoneHematomaHumansNeutrophilsReceptor, Anaphylatoxin C5aBacterial ProteinsC5AR1 protein, humanchemotaxis inhibitory protein, Staphylococcus aureusReceptor, Anaphylatoxin C5aC5aRCHIPSCHIPSΔ1FCXCR1/2fractureneutrophil

Identifiers

PMID29511935
PMCPMC5982450
OpenAlexW2790877381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.